Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease [5]

Journal of Neurology

Volumn 248, Issue 6, 2001, Pages 533-534

  Ito, Daisuke ^a   Amano, Takahiro ^a   Sato, Hideki ^a   Fukuuchi, Yasuo ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CARBIDOPA; MONOAMINE OXIDASE INHIBITOR; SELEGILINE; TALIPEXOLE;

DRUG EFFECT; DYSKINESIA; HEADACHE; HUMAN; HYPERTENSION; LETTER; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL;

ACUTE DISEASE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; SELEGILINE;

EID: 0034911260     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150170168     Document Type: Letter

References (13)

1. Autonomic effects of selegiline: Possible cardiovascular toxicity in Parkinson's disease
2. Selegiline-induced postural hypotension in Parkinson's disease: A longitudinal study on the effects of drug withdrawal
3. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
4. A review of the pharmacology of selegiline
5. Catecholamines and sympathomimetic drugs
6. Potential fluoxetine-selegiline interaction
7. Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline
8. Monoamine oxidase inhibitors. An update on drug interactions
9. A possible L-deprenyl induced hypertensive reaction
10. Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline
11. Serotonin syndrome and the combined use of deprenyl and an anti-depressant in Parkinson's disease
12. Interaction of fluoxetine and selegiline
13. Severe adverse interaction between pethidine and selegiline